[AVEO] AVEO Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.6 Change: 0.02 (3.69%)
Ext. hours: Change: 0 (0%)

chart AVEO

Refresh chart

Description: AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, a biopharmaceutical company, is engaged in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its therapeutic candidates under development program include AV-203, an anti-ErbB3 monoclonal antibody that has completed a Phase 1 dose escalation study; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase 2 trial; Tivozanib, an investigational tyrosine kinase inhibitor of various vascular endothelial growth factor receptors; and AV-380 Program, a program focusing on cachexia, a serious and common complication of advanced cancer, as well as a range of chronic diseases that is characterized by unintentional weight loss, progressive muscle wasting, and a loss of appetite. AVEO Pharmaceuticals, Inc. has strategic partnerships with St. Vincent?s Hospital Sydney Limited; Kyowa Hakko Kirin; Biogen Idec, Inc.; OSI Pharmaceuticals, Inc.; Centocor Ortho Biotech Inc.; and Merck & Co.,

Fundamental Ratios
Shares Outstanding EPS-0.39 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -92.74% Sales Growth - Q/Q15.52% P/E-1.95
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-114.32% ROE-391.69% ROI-243.81%
Current Ratio1.67 Quick Ratio Long Term Debt/Equity0.46 Debt Ratio1.82
Gross Margin Operating Margin-1843.19% Net Profit Margin-1925.98% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.67 M Cash From Investing Activities-3.62 M Cash From Operating Activities-15.82 M Gross Profit
Net Profit-10.87 M Operating Profit-10.15 M Total Assets50 M Total Current Assets44.42 M
Total Current Liabilities26.55 M Total Debt18.02 M Total Liabilities35.41 M Total Revenue130 K
Technical Data
High 52 week3.48 Low 52 week0.59 Last close0.66 Last change5.76%
RSI54.47 Average true range0.05 Beta1.05 Volume244.22 K
Simple moving average 20 days-16.37% Simple moving average 50 days-53.57% Simple moving average 200 days-69.38%
Performance Data
Performance Week6.92% Performance Month-61.79% Performance Quart-66.95% Performance Half-72.11%
Performance Year-76.89% Performance Year-to-date-58.69% Volatility daily20.49% Volatility weekly45.82%
Volatility monthly93.91% Volatility yearly325.31% Relative Volume297.41% Average Volume3.32 M
New High New Low

News

2020-06-02 11:41:03 | FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma

2020-06-02 04:00:52 | Aveo’s Tivozanib Gets FDA Nod For New Drug Application To Treat Kidney Cancer

2020-06-01 13:15:00 | AVEO Oncology Announces FDA Acceptance for Filing of a New Drug Application for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma

2020-06-01 08:52:12 | Implied Volatility Surging for AVEO Pharmaceuticals AVEO Stock Options

2020-05-30 11:31:03 | Why Is AVEO AVEO Up 24.8% Since Last Earnings Report?

2020-05-29 07:05:00 | AVEO Oncology Announces Phase 1b/2 DEDUCTIVE Study of FOTIVDA® tivozanib in Combination with IMFINZI® durvalumab in Previously Untreated Metastatic Hepatocellular Carcinoma Advances to Phase 2

2020-05-29 07:00:00 | AVEO Oncology Announces TIVO-3 Final Overall Survival Results Featured at ASCO 2020 Virtual Scientific Program and Submitted to U.S. FDA as Part of NDA Filing

2020-05-27 16:05:00 | AVEO Announces Change to Virtual Annual Meeting of Stockholders

2020-05-12 08:50:12 | Why You Shouldn't Bet Against AVEO Pharmaceuticals AVEO Stock

2020-04-30 09:55:01 | AVEO Pharmaceuticals AVEO Reports Q1 Loss, Lags Revenue Estimates

2020-04-30 07:00:00 | AVEO Oncology Reports First Quarter 2020 Financial Results and Provides Business Update

2020-04-29 14:30:00 | AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program

2020-04-15 11:30:03 | AVEO AVEO Up 39.9% Since Last Earnings Report: Can It Continue?

2020-03-31 16:05:00 | AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma

2020-03-30 11:54:03 | AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic

2020-03-27 16:40:00 | AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

2020-03-17 11:52:03 | AVEO Pharmaceuticals AVEO Q4 Earnings Beat & Sales Miss

2020-03-16 17:25:09 | AVEO Pharmaceuticals AVEO Reports Q4 Loss, Lags Revenue Estimates

2020-03-16 16:05:00 | AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update

2020-03-05 12:30:05 | AVEO Pharmaceuticals AVEO Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

2020-02-26 12:00:05 | What Makes AVEO AVEO a New Buy Stock

2020-02-19 09:08:00 | AVEO Announces Effectiveness of 1-for-10 Reverse Stock Split

2020-02-13 08:05:12 | The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

2020-02-12 16:26:00 | AVEO Oncology Announces Publication of Phase 1b/2 Study of Tivozanib in Advanced, Inoperable Liver Cancer in the British Journal of Cancer

2020-01-28 11:14:28 | AVEO Posts Data on Ficlatuzumab From Pancreatic Cancer Study

2020-01-27 07:00:00 | AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

2020-01-06 07:00:00 | AVEO Announces Appointment of Erick J. Lucera as Chief Financial Officer

2019-12-20 17:34:42 | Is AVEO Pharmaceuticals, Inc. AVEO Going To Burn These Hedge Funds ?

2019-12-20 10:25:03 | Implied Volatility Surging for AVEO Pharmaceuticals AVEO Stock Options

2019-12-12 11:30:04 | Why Is AVEO AVEO Down 0.1% Since Last Earnings Report?

2019-12-04 07:00:00 | AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma

2019-11-26 07:00:00 | AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference

2019-11-19 07:00:00 | AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors

2019-11-18 06:00:00 | AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma

2019-11-15 08:57:01 | Sarepta SRPT Stock Down Despite New $48M Gene Therapy Deal

2019-11-13 13:14:06 | AVEO Pharmaceuticals AVEO Q3 Earnings & Revenues Top Mark

2019-11-12 07:00:00 | AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update

2019-11-08 10:08:03 | Spectrum Pharma's SPPI Q3 Loss Narrows, Focus on Rolontis

2019-11-08 10:00:03 | Global Blood's GBT Q3 Loss Widens, Voxelotor in Focus

2019-11-07 11:08:04 | Zoetis ZTS Beats on Earnings in Q3, Reports In-Line Sales

2019-11-07 11:05:04 | Horizon Therapeutics' HZNP Q3 Earnings Beat Estimates

2019-11-07 07:00:00 | AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML

2019-11-06 11:00:04 | Ultragenyx RARE Reports Wider-Than-Expected Loss in Q3

2019-11-06 10:34:03 | Intercept ICPT Earnings and Sales Miss Estimates in Q3

2019-11-04 07:00:00 | AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma

2019-11-01 10:30:02 | AVEO Pharmaceuticals AVEO Earnings Expected to Grow: Should You Buy?

2019-10-22 09:32:01 | AVEO Sees Hammer Chart Pattern: Time to Buy?

2019-10-17 08:58:12 | Reata RETA Jumps: Stock Rises 5. 6%

2019-10-16 09:00:01 | AVEO AVEO Upgraded to Strong Buy: What Does It Mean for the Stock?

2019-09-30 07:00:00 | AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® tivozanib in Combination with IMFINZI® durvalumab in Previously Untreated Metastatic Hepatocellular Carcinoma